Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Business Wire•12/11/2026•16:05 ET
0
Key Highlights
- ➤EVO570 licensed from Hinova for $30 million upfront, including $20 million cash.
- ➤EVO301 cut EASI 55% at Week 12 versus 22% placebo in Phase 2a AD trial.
- ➤EVO301 Phase 2b atopic dermatitis trial expected to begin mid-2027.
- ➤Evommune raised approximately $30 million through a concurrent private placement.
- ➤Third-quarter net loss widened to $30.9 million from $12.5 million year over year.
Expert Statements
Luis Peña, President and Chief Executive Officer at Evommune
“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved.”
Luis Peña, President and Chief Executive Officer at Evommune
“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
- Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV1 molecular glue degrader
Get started
Create a free account to read the full story.